ymjЯкутский медицинский журналYakut Medical Journal1813-19052312-1017ЯНЦ КМП10.25789/YMJ.2020.69.08ymj-2924Research ArticleМЕТОДЫ ДИАГНОСТИКИ И ЛЕЧЕНИЯMETHODS OF DIAGNOSIS AND TREATMENTТерапия больных раком молочной железы с тревожно-депрессивными расстройствамиTherapy of patients with breast cancer with anxiety and depressive disordersШушпановаО. В.ShushpanovaO. V.

ШУШПАНОВА Ольга Владимировна – н.с.

SHUSHPANOVA Olga Vladimirovna – Researcher

34 Kashirskoye Shosse, 115522, Moscow

sertraline@list.ruИвановС. В.IvanovS. V.

ИВАНОВ Станислав Викторович – д.м.н., проф., гл.н.с.

IVANOV Stanislav Viktorovich – PhD, MD, Professor, Chief Researcher

34 Kashirskoye Shosse, 115522, Moscow

stanislvi@gmail.comШушпановаТ. В.ShushpanovaT. V.

ШУШПАНОВА Тамара Владимировна – к.м.н, в.н.с.

SHUSHPANOVA Tamara Vladimirovna – PhD., MD, Leading Scientific Researcher

634014, Tomsk, Aleutskaya 4

shush59@mail.ruНаучный центр психического здоровья РАНРоссияMental Health Research Center of the Russian Academy of SciencesRussian FederationНИИ психического здоровья Томского национального исследовательского медицинского центра РАНРоссияMental Health Research Institute “Tomsk National Research Medical Center of the Russian Academy of Sciences”Russian Federation202021112025013438Copyright © Шушпанова О.В., Иванов С.В., Шушпанова Т.В., 20252025Шушпанова О.В., Иванов С.В., Шушпанова Т.В.Shushpanova O.V., Ivanov S.V., Shushpanova T.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://ymj.elpub.ru/jour/article/view/2924

Исследовались пациентки с гистологически верифицированным раком молочной железы, включая с впервые диагностированным РМЖ и с длительностью катамнеза 3–17 лет. В клинической картине у обследуемых выявлены депрессивные, тревожно–фобические и психосоматические расстройства, что в значительной степени снижало их качество жизни и отрицательно влияло на прогноз и выживаемость пациентов. Проведение специализированной фармакотерапии с применением антидепрессантов в комбинации с препаратами бензодиазепинового ряда и гипнотиками у больных РМЖ выявило высокие показатели эффективности проводимой комбинированной терапии.

Female patients with histologically verified breast cancer, including newly diagnosed breast cancer and with a history of 3-17 years were under study. In the clinical picture of the examined patients, depressive, anxious-phobic and psycho-somatic disorders were identified, which significantly reduced their quality of life and adversely affected the prognosis and survival of patients. Conducting specialized pharmacotherapy with the use of antidepressants in combination with benzodiazepine drugs and hypnotics in breast cancer patients revealed high efficacy of the combination therapy.

рак молочной железытревожностьдепрессивное расстройствоbreast canceranxietydepressive disorderReferencesВолодин Б.Ю. Психосоматические взаимоотношения у онкологических больных / Б.Ю. Володин // Паллиативная медицина и реабилитация. – 2007. – № 3. – С. 51-54.Volodin B.Yu. Psychosomatic relationships in cancer patients. /B.Yu. Volodin //Palliative medicine and rehabilitation. – 2007. – № 3. – рр. 51-54.Галиуллина С.Д. Нервно-психические нарушения у больных раком молочной железы: автореф. дис. канд. мед. наук / С.Д. Галиуллина. – Уфа, 2000. – 23 с.Galiullina S.D. Neuropsychiatric disorders in patients with breast cancer: Abstract dis. cand. med. sciences / S.D. Galiullina – Ufa, 2000. – 23 p.Злокачественные новообразования в Якутии. Заболеваемость и смертность / Под ред. П.М. Иванова, Л.Н. Афанасьевой, С.А. Мыреевой. – Якутск, 2018. – 180 с.Malignant neoplasms in Yakutia (morbidity and mortality) / under P.M. Ivanov, L.N. Afanasieva, S.A. Myreeva ed. – Yakutsk, 2018. – 180 p.Самушия М.А. Нозогении (психогенные реакции) при раке молочной железы, / М.А. Самушия, И.В. Зубова // Психические расстройства в общей медицине. – 2009. – № 1. – С. 24-29.Samushia M. A. Nosogeny (psychogenic reactions) in breast cancer / M.A. Samushia, I.V. Zubova // Mental disorders in general medicine. – 2009. – № 1. – P. 24-29.Злокачественные новообразования в России в 2015 году (заболеваемость и смертность) / Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. – М., 2017. – 250 с.Malignant neoplasms in Russia in 2015 (morbidity and mortality) / under A.D. Kaprin, V.V. Starinsky, G.V. Petrova ed. – M., 2017. – 250 p.Шушпанова О.В. Психические нарушения у больных раком молочной железы: дифференцированный подход к изучению нозогений / О.В. Шушпанова // Журнал неврологии и психиатрии им. С.С. Корсакова. – 2017. – Т.117(8). – С.18–26. doi: 10.17116/jnevro20171178118-26.Shushpanova O.V. Mental disorders in patients with breast cancer: a differentiated approach to the study of nosogeny / O.V. Shushpanova, S.S. Korsakov // Journal of Neurology and Psychiatry. – 2017. – V.117 (8). – pp. 18–26. doi: 10.17116/jnevro20171178118-26.A systematic review and meta-analysis of prescribing practices of antidepressants in cancer patients / S. Sanjida, M. Janda, D. Kissane [et al.] // Psychooncology. – 2016. – V. 25(9). – pp. 1002-1016. doi: 10.1002/pon.4048.A systematic review and meta-analysis of prescribing practices of antidepressants in cancer patients / S. Sanjida, M. Janda, D. Kissane [et al.] // Psychooncology. – 2016. – V. 25(9). – pp. 1002-1016. doi: 10.1002/pon.4048.Attentional bias and metacognitions in cancer survivors with high fear of cancer recurrence. / P. Butow, S. Kelly, B. Thewes [et al.] // Psychooncology. – 2015. – V. 24(4). – pp. 416-423. doi: 10.1002/pon.3659.Attentional bias and metacognitions in cancer survivors with high fear of cancer recurrence. / P. Butow, S. Kelly, B. Thewes [et al.] // Psychooncology. – 2015. – V. 24(4). – pp. 416-423. doi: 10.1002/pon.3659.Duloxetine and escitalopram for hot flushes: efficacy and compliance in breast cancer survivors. N. Biglia, V. E Bounous, T. Susini [et al]. // Eur. J. Cancer Care (Engl). – 2018. – 27(1). doi: 10.1111/ecc.12484.Duloxetine and escitalopram for hot flushes: efficacy and compliance in breast cancer survivors. N. Biglia, V. E Bounous, T. Susini [et al]. // Eur. J. Cancer Care (Engl). – 2018. – 27(1). doi: 10.1111/ecc.12484.Effect of paroxetine hydrochloride (Paxil) on fatigue and depression in breast cancer patients receiving chemotherapy / J. A Roscoe., G. R Morrow., J. T. Hickok [et al.] // Breast Cancer Res. Treat. – 2005. – V. 89(3). – pp. 243-249. doi: 10.1007/s10549-004-2175-1.Effect of paroxetine hydrochloride (Paxil) on fatigue and depression in breast cancer patients receiving chemotherapy / J. A Roscoe., G. R Morrow., J. T. Hickok [et al.] // Breast Cancer Res. Treat. – 2005. – V. 89(3). – pp. 243-249. doi: 10.1007/s10549-004-2175-1.Efficacy and safety of pharmacotherapy in cancer-related psychiatric disorders across the trajectory of cancer care: a review / L. Grassi, R. Caruso, K. Hammelef [et al.] // Int. Rev. Psychiatry. – 2014. – V. 26(1). – pp. 44–62. doi: 10.3109/09540261.2013.84254.Efficacy and safety of pharmacotherapy in cancer-related psychiatric disorders across the trajectory of cancer care: a review / L. Grassi, R. Caruso, K. Hammelef [et al.] // Int. Rev. Psychiatry. – 2014. – V. 26(1). – pp. 44–62. doi: 10.3109/09540261.2013.84254.Ersoy M.A. An Open-Label Long-Term Naturalistic Study of Mirtazapine Treatment for Depression in Cancer Patients / M. A. Ersoy, A. M. Noyan, H. Elbi // Clin Drug Investig. – 2008. – V. 28(2). – pp. 113–20. doi: 10.2165/00044011-200828020-00005.Ersoy M.A. An Open-Label Long-Term Naturalistic Study of Mirtazapine Treatment for Depression in Cancer Patients / M. A. Ersoy, A. M. Noyan, H. Elbi // Clin Drug Investig. – 2008. – V. 28(2). – pp. 113–20. doi: 10.2165/00044011-200828020-00005.Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology / D. S. Baldwin, I. M. Anderson, D. J. Nutt [et al.] // J. Psychopharmacol. – 2014. – V. 28(5). – pp. 403–439. doi: 10.1177/0269881114525674.Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology / D. S. Baldwin, I. M. Anderson, D. J. Nutt [et al.] // J. Psychopharmacol. – 2014. – V. 28(5). – pp. 403–439. doi: 10.1177/0269881114525674.Frampton J. E. Duloxetine: a review of its use in the treatment of major depressive disorder / J.E Frampton, G.L. Plosker // CNS Drugs. – 2007. – V. 21. – pp. 581-609. doi:10.2165/00023210-200721070-00004.Frampton J. E. Duloxetine: a review of its use in the treatment of major depressive disorder / J.E Frampton, G.L. Plosker // CNS Drugs. – 2007. – V. 21. – pp. 581-609. doi:10.2165/00023210-200721070-00004.Interactions between antidepressants, sleep aids and selected breast cancer therapy / J. J. Wedret, T.G. Tum, D. Paul [et al.] // Ment Illn. – 2019. – V. 11(1). – pp. 8115. doi: 10.4081/mi.2019.8115.Interactions between antidepressants, sleep aids and selected breast cancer therapy / J. J. Wedret, T.G. Tum, D. Paul [et al.] // Ment Illn. – 2019. – V. 11(1). – pp. 8115. doi: 10.4081/mi.2019.8115.Irarrázaval O.M.E. Antagonism of tamoxifen and antidepressants among women with breast cancer. / O.M.E. Irarrázaval // Rev. Med. Chil. –2011. – V. 139(1). – pp. 89-99. doi: 10.4067/S0034-98872011000100013.Irarrázaval O.M.E. Antagonism of tamoxifen and antidepressants among women with breast cancer. / O.M.E. Irarrázaval // Rev. Med. Chil. –2011. – V. 139(1). – pp. 89-99. doi: 10.4067/S0034-98872011000100013.Kalso E. Amitriptyline effectively relieves neuropathic pain following treatment of breast cancer. / E. Kalso, T. Tasmuth, P.J. Neuvonen // Pain. 1996; 64(2): 293-302. doi:10.1016/0304-3959(95)00138-7.Kalso E. Amitriptyline effectively relieves neuropathic pain following treatment of breast cancer. / E. Kalso, T. Tasmuth, P.J. Neuvonen // Pain. 1996; 64(2): 293-302. doi:10.1016/0304-3959(95)00138-7.Liebowitz M.R. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder / M.R. Liebowitz, A.J. Gelenberg, D. Munjack //Arch Gen Psychiatry. 2005; 62:190-198. doi: 10.1001/archpsyc.62.2.190.Liebowitz M.R. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder / M.R. Liebowitz, A.J. Gelenberg, D. Munjack //Arch Gen Psychiatry. 2005; 62:190-198. doi: 10.1001/archpsyc.62.2.190.Major depressive disorder in breast cancer: a critical systematic review of pharmacological and psychotherapeutic clinical trials / A.F. Carvalho, T. Hyphantis, P.M. Sales [et al.] // Cancer Treat Rev. – 2014. – V. 40(3). – pp. 349-355. doi: 10.1016/j.ctrv.2013.09.009Major depressive disorder in breast cancer: a critical systematic review of pharmacological and psychotherapeutic clinical trials / A.F. Carvalho, T. Hyphantis, P.M. Sales [et al.] // Cancer Treat Rev. – 2014. – V. 40(3). – pp. 349-355. doi: 10.1016/j.ctrv.2013.09.009Metabolic Drug Interactions Between Antidepressants and Anticancer Drugs: Focus on Selective Serotonin Reuptake Inhibitors and Hypericum Extract / F. Caraci, R. Crupi, F. Drago [et al.] // Current Drug Metabolism. – 2011. – V. 12(6). – pp. 570-577. doi:10.2174/138920011795713706Metabolic Drug Interactions Between Antidepressants and Anticancer Drugs: Focus on Selective Serotonin Reuptake Inhibitors and Hypericum Extract / F. Caraci, R. Crupi, F. Drago [et al.] // Current Drug Metabolism. – 2011. – V. 12(6). – pp. 570-577. doi:10.2174/138920011795713706Navari R.M. Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy / R.M. Navari, M.C. Brenner, M.N. Wilson // Breast Cancer Res Treat. – 2008. – V.112(1). – pp. 197–201. doi: 10.1007/s10549-007-9841-z.Navari R.M. Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy / R.M. Navari, M.C. Brenner, M.N. Wilson // Breast Cancer Res Treat. – 2008. – V.112(1). – pp. 197–201. doi: 10.1007/s10549-007-9841-z.Pharmacogenetics of escitalopram and mental adaptation to cancer in palliative care: report of 18 cases / G. Schillani, M.A. Capozzo, D. Era [et al.] // Tumori. – 2011. – V. 97(3). – 358–361. doi: 10.1700/912.10034.Pharmacogenetics of escitalopram and mental adaptation to cancer in palliative care: report of 18 cases / G. Schillani, M.A. Capozzo, D. Era [et al.] // Tumori. – 2011. – V. 97(3). – 358–361. doi: 10.1700/912.10034.Pezzella G. Treatment of depression in patients with breast cancer: a comparison between paroxetine and amitriptyline / G.Pezzella, R. Moslinger-Gehmayr, A. Contu A. // Breast Cancer Res. Treat. – 2001. – V. 70(1). – pp.1-10. doi: 10.1023/a:1012518831494.Pezzella G. Treatment of depression in patients with breast cancer: a comparison between paroxetine and amitriptyline / G.Pezzella, R. Moslinger-Gehmayr, A. Contu A. // Breast Cancer Res. Treat. – 2001. – V. 70(1). – pp.1-10. doi: 10.1023/a:1012518831494.Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen. / G.G. Kimmick, J. Lovato, R. McQuellon [et al.] // Breast J. – 2006. – V.12(2). – pp. 114-122. doi: 10.1111/j.1075-122X.2006.00218.xRandomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen. / G.G. Kimmick, J. Lovato, R. McQuellon [et al.] // Breast J. – 2006. – V.12(2). – pp. 114-122. doi: 10.1111/j.1075-122X.2006.00218.xRustad J.K. Cancer and post-traumatic stress disorder: diagnosis, pathogenesis and treatment considerations / J.K. Rustad, D. David, M.B. Currier // Pall Supp Care. – 2012. – V. 10(3). – pp. 213–223. doi: 10.1017/S1478951511000897.Rustad J.K. Cancer and post-traumatic stress disorder: diagnosis, pathogenesis and treatment considerations / J.K. Rustad, D. David, M.B. Currier // Pall Supp Care. – 2012. – V. 10(3). – pp. 213–223. doi: 10.1017/S1478951511000897.The pharmacological and hormonal therapy of hot flushes in breast cancer survivors. / I. Wiśniewska, B. Jochymek, M. Lenart-Lipińska [et al.] // Breast Cancer. – 2016. – V. 23. – pp. 178–182. doi: 10.1007/s12282-015-0655-2.The pharmacological and hormonal therapy of hot flushes in breast cancer survivors. / I. Wiśniewska, B. Jochymek, M. Lenart-Lipińska [et al.] // Breast Cancer. – 2016. – V. 23. – pp. 178–182. doi: 10.1007/s12282-015-0655-2.The use of antidepressants in oncology: a review and practical tips for oncologists. / L. Grassi, M.G. Nanni, G. Rodin [et al.] // Ann Oncol. – 2018. – V. 29(1). – pp. 101-111. doi: 10.1093/annonc/mdx526.The use of antidepressants in oncology: a review and practical tips for oncologists. / L. Grassi, M.G. Nanni, G. Rodin [et al.] // Ann Oncol. – 2018. – V. 29(1). – pp. 101-111. doi: 10.1093/annonc/mdx526.Torta R. Duloxetine for the treatment of mood disorder in cancer patients: a 12-week case-control clinical trial / R. Torta, P. Leombruni, R. Borio R., Castelli L. // Hum. Psychopharmacol. – 2011. – V. 26. – pp. 291-299. doi: 10.1002/hup.1202.Torta R. Duloxetine for the treatment of mood disorder in cancer patients: a 12-week case-control clinical trial / R. Torta, P. Leombruni, R. Borio R., Castelli L. // Hum. Psychopharmacol. – 2011. – V. 26. – pp. 291-299. doi: 10.1002/hup.1202.Venlafaxine in management of hot flashes in women with breast cancer: a systematic review and meta-analysis / R. Ramaswami, M. D. Villarreal, D. M. Pitta [et al.] // Breast Cancer Res. Treat. – 2015. – V. 152(2). – pp. 231-237. doi: 10.1007/s10549-015-3465-5.Venlafaxine in management of hot flashes in women with breast cancer: a systematic review and meta-analysis / R. Ramaswami, M. D. Villarreal, D. M. Pitta [et al.] // Breast Cancer Res. Treat. – 2015. – V. 152(2). – pp. 231-237. doi: 10.1007/s10549-015-3465-5.

The authors declare that there are no conflicts of interest present.